XCancer

Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases

Description:

This study aims to evaluate the diagnostic potential of 68-Gallium PSMA-PET/CT in stereotactic irradiated brain metastases from non-small cell lung cancer, melanoma and breast cancer.

Sponsor:

The Netherlands Cancer Institute

Phase:

N/A

Contacts:

Dieta Brandsma, MD, PhD (CONTACT)

Dieta Brandsma, MD, PhD (PRINCIPAL_INVESTIGATOR)

Lente Kroon, MD (CONTACT)

neurologie@nki.nl

0031205129111

Government Study Link:

NCT07511933 - Click here to see study on

ClinicalTrials.gov

PSMA-11

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: HBED-CC
Inclusion
  • Measurable lesion ≥10mm according to RANO BMFor brain metastases groups:\- newly diagnosed brain metastases from either NSCLC (group 1) or melanoma (group 2) or breast cancer (group 7).For radiation necrosis groups:\- Brain lesion at the location of a formerly brain metastases that has been treated with SRT (\> 9 months ago), with the definite diagnosis of radiation necrosis at the location of formerly SRT-treated brain metastases of NSCLC (group 3), melanoma (group 4) and/ or breast cancer (group 8).For diagnostic dilemma groups:\- Brain lesion at the location of a formerly brain metastases with a diagnostic dilemma of radiation necrosis and recurrent brain metastases of NSCLC (group 5), melanoma (group 6) and/ or breast cancer (group 9).
  • WHO PS 0-3
Exclusion
  • Epileptic seizure less than 7 days before Ga68-PSMA PET/CT scan